{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:04:50Z","timestamp":1764745490726,"version":"3.46.0"},"reference-count":38,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<p\/>","DOI":"10.17925\/ee.2020.16.2.109","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T15:09:56Z","timestamp":1602688196000},"page":"109","source":"Crossref","is-referenced-by-count":2,"title":["Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome \u2013 Clearing Safety Issues and Good Clinical Practice"],"prefix":"10.17925","volume":"16","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism (CEDAR) Superspeciality Clinics, Dwarka, New Delhi, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meha","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Rheumatology, CEDAR Superspeciality Clinics, Dwarka, New Delhi, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pulmonary Medicine, Le Crest Hospital, Ghaziabad, Uttar Pradesh, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.\n                      J Antimicrob Chemothe\n                      r\n                      . 2020;75:1667\u201370.","DOI":"10.1093\/jac\/dkaa114"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Tripathy S, Dassarma B, Roy S, et al. A review on possible modes of action of chloroquine\/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.\n                      Int J Antimicrob Agents\n                      . 2020;56:106028.","DOI":"10.1016\/j.ijantimicag.2020.106028"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ren L, Xu W, Overton JL, et al. Assessment of hydroxychloroquine and chloroquine safety profiles: a systematic review and meta-analysis.\n                      medRxiv\n                      . 2020; doi: 10.1101\/2020.05.02.20088872 [Online ahead of print].","DOI":"10.1101\/2020.05.02.20088872"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.\n                      Int J Infect Dis\n                      . 2020;94:91\u20135.","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"ref5","unstructured":"He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients.\n                      Zhonghua Xin Xue Guan Bing Za Zhi\n                      . 2020;48:E011."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Shaikh K, Shrestha C, Dutta D. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.\n                      J Pak Med Assoc\n                      . 2020;70(Suppl. 3):S69\u201373.","DOI":"10.5455\/JPMA.22"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.\n                      Virol J\n                      . 2005;2:69.","DOI":"10.1186\/1743-422X-2-69"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Khan M, Santhosh SR, Tiwari M, et al. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells.\n                      J Med Virol\n                      . 2010;82:817\u201324.","DOI":"10.1002\/jmv.21663"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wang LF, Lin YS, Huang NC, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery.\n                      J Interferon Cytokine Res\n                      . 2015;35:143\u201356.","DOI":"10.1089\/jir.2014.0038"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study.\n                      Clin Rheumatol\n                      . 2017;36:1335\u201340.","DOI":"10.1007\/s10067-016-3429-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.\n                      Nat Rev Rheumatol\n                      . 2020;16:155\u201366.","DOI":"10.1038\/s41584-020-0372-x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chatterjee P, Anand T, Singh KJ, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.\n                      Indian J Med Res\n                      . 2020;151:459-67","DOI":"10.4103\/ijmr.IJMR_2234_20"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.\n                      Biosci Trends\n                      . 2020;14:72\u20133.","DOI":"10.5582\/bst.2020.01047"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.\n                      Int J Antimicrob Agents\n                      . 2020;56:105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ishaqui AA, Khan AH, Sulaiman SAS, et al. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief.\n                      Expert Rev Respir Med\n                      . 2020;14:533\u201341.","DOI":"10.1080\/17476348.2020.1730180"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li C, Zu S, Deng YQ, et al. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses.\n                      Antimicrob Agents Chemother\n                      . 2019;63:e00394\u201319.","DOI":"10.1128\/AAC.00394-19"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zeng S, Meng X, Huang Q, et al. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo.\n                      Int J Antimicrob Agents\n                      . 2019;53:362\u20139.","DOI":"10.1016\/j.ijantimicag.2018.12.009"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Paccoud O, Tubach F, Baptiste A, et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe COVID-19 in a French university hospital.\n                      Clin Infect Dis\n                      . 2020; doi: 10.1093\/cid\/ciaa791 [Online ahead of print].","DOI":"10.1093\/cid\/ciaa791"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.\n                      BMJ\n                      . 2020;369:m1849.","DOI":"10.1136\/bmj.m1849"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.\n                      Lancet\n                      . 2020; doi: 10.1016\/S0140-6736(20)31180\u20136.","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.\n                      Lancet\n                      . 2020;395:1054\u201362.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"ref22","unstructured":"Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].\n                      Zhonghua Jie He He Hu Xi Za Zhi\n                      . 2020;43:185\u20138."},{"key":"ref23","unstructured":"Korea Biomedical Review. Physicians work out treatment guidelines for coronavirus. 2020. Available at: www.koreabiomed.com\/news\/articleView.html?idxno=7428 (accessed 8 June 2020)."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Marmor MF, Kellner U, Lai TY, et al; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).\n                      Ophthalmology\n                      . 2016;123:1386\u201394.","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Capel RA, Herring N, Kalla M, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current\n                      If\n                      : novel electrophysiological insights and therapeutic potential.\n                      Heart Rhythm\n                      . 2015;12:2186\u201394.","DOI":"10.1016\/j.hrthm.2015.05.027"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Cairoli E, Danese N, Teliz M, et al. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.\n                      Lupus\n                      . 2015;24:1204\u20139.","DOI":"10.1177\/0961203315580870"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kim JW, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine.\n                      J Rheumatol\n                      . 2017;44:1674\u20139.","DOI":"10.3899\/jrheum.170158"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Couturier A, Giocanti-Aur\u00e9gan A, Dupas B, et al; DHU Vision, and Handicap Task Force R\u00e9tine. Update on recommendations for screening for hydroxychloroquine retinopathy.\n                      J Fr Ophtalmol\n                      . 2017;40:793\u2013800.","DOI":"10.1016\/j.jfo.2017.08.002"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature.\n                      Drug Saf\n                      . 2018;41:919\u201331.","DOI":"10.1007\/s40264-018-0689-4"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Wu CL, Chang CC, Kor CT, et al. Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis.\n                      Clin J Am Soc Nephrol\n                      . 2018;13:702\u20139.","DOI":"10.2215\/CJN.11781017"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tang TT, Lv LL, Pan MM, et al. Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation.\n                      Cell Death Dis\n                      . 2018;9:351.","DOI":"10.1038\/s41419-018-0378-3"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Liu LJ, Yang YZ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial.\n                      Am J Kidney Dis\n                      . 2019;74:15\u201322.","DOI":"10.1053\/j.ajkd.2019.01.026"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, McGwin G Jr, et al. Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.\n                      Arthritis Rheum\n                      . 2009;61:830\u20139.","DOI":"10.1002\/art.24538"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Browning DJ. Pharmacology of chloroquine and hydroxychloroquine.\n                      Hydroxychloroquine and Chloroquine Retinopathy\n                      . 2014;35\u201363.","DOI":"10.1007\/978-1-4939-0597-3_2"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Tailor R, Elaraoud I, Good P, et al. A case of severe hydroxychloroquine-induced retinal toxicity in a patient with recent onset of renal impairment: a review of the literature on the use of hydroxychloroquine in renal impairment.\n                      Case Rep Ophthalmol Med\n                      . 2012;2012:182747.","DOI":"10.1155\/2012\/182747"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sharma M, Kumar M, Dutta D. Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.\n                      Diabet Med\n                      . 2020;37:1404\u20135.","DOI":"10.1111\/dme.14144"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Wiacek MP, Bobrowska-Snarska D, Lubi\u0144ski W, et al. What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review.\n                      Niger J Clin Pract\n                      . 2017;20:919\u201323.","DOI":"10.4103\/njcp.njcp_380_16"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Ng HH, Narasaraju T, Phoon MC, et al. Doxycycline treatment attenuates acute lung injury in mice infected with virulent influenza H3N2 virus: involvement of matrix metalloproteinases.\n                      Exp Mol Pathol\n                      . 2012;92:287\u201395.","DOI":"10.1016\/j.yexmp.2012.03.003"}],"container-title":["European Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/covid-19\/journal-articles\/short-term-hydroxychloroquine-in-covid-19-infection-in-people-with-or-without-metabolic-syndrome-clearing-safety-issues-and-good-clinical-practice\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:48Z","timestamp":1764745188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/covid-19\/journal-articles\/short-term-hydroxychloroquine-in-covid-19-infection-in-people-with-or-without-metabolic-syndrome-clearing-safety-issues-and-good-clinical-practice\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["EE.2020.16.2.109"],"URL":"https:\/\/doi.org\/10.17925\/ee.2020.16.2.109","relation":{},"ISSN":["1758-3772"],"issn-type":[{"type":"print","value":"1758-3772"}],"subject":[],"published":{"date-parts":[[2020]]}}}